Categories: New Launches

Trivitron Healthcare launches two new tests in the Newborn screening panel

New Delhi, August 08, 2015:  Trivitron healthcare, India’s largest medical technology company of Indian origin has added two new products in the Newborn Screening kit for India. With this launch, they aim to create better future for newborn babies in the country by providing corrective diagnosis at birth. The two new tests are Neonatal IRTand Neonatal Toxoplasma gondii IgM that detect disorders which may harm the newborn in later stages of life.

Trivitron is offering a wide range of Newborn screening assays already in the market through the Labsystems diagnostics brand, among those areTSH, PKU, 17OHP, G6PD, Galactose and Toxoplasmi gondii. Together with its fully automated NS2400 platform, Trivitronhas launchedtwo new products to complement its newborn screening panel.Neonatal IRT can detect disorders affecting the lungs, pancreas, intestine and liver. Whereas, Neonatal Toxoplasma gondii IgM can detect neurological and visual disabilities. With Newborn screening tests, the parents can start taking precautions in the early stages of life and prevent the child from life-long disorders. Majority of infants infected in utero are asymptomatic at birth, particularly if maternal infection occurs during third trimester, with sequel appearing later in life. Congenital toxoplasmosis results in severe generalized or neurological disease in about 20% to 30% of the infants infected in utero; approximately 10% exhibit visual involvement only and the remainder are asymptomatic at birth.

Dr. GSK Velu, Founder and Managing Director of Trivitron Group ofcompanies said, “Trivitron Healthcare is taking strong steps towards women and child healthcare diagnosis. The thought behind adding two critical tests to the kit is to eradicate detected problems in the newborn at early stages for better lifestyle and to live a carefree life. Trivitron is known for its innovation in medical technology sector and making it available and affordable to larger section of the population across the globe”.

If untreated during the early stages, problems will start appearing during their teens. Brain and nervous system damage ranges from very mild to severe, and may include Seizures and Intellectual disability.
CCI Newswire

The Pharma Times News Bureau

Recent Posts

World Diabetes Day Survey: Diabetologists and Endocrinologists demand for AI-Based Training and Upskilling in Diabetes Care

 A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…

14 hours ago

Doctors warn diabetes patients about risk of smoking

People who smoke are also at much higher risk of developing diabetes compared to non-smokers…

2 days ago

CPHI & PMEC India Expo: Encouraging affordable solutions in India’s march towards a $130 Billion Pharma Market by 2030

17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…

2 days ago

Sringeri Sharada Equitas Hospital Revolutionizing Cancer Care with the Launch of Low-cost, High Quality Radiation Therapy

The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…

3 days ago